Dechra Pharmaceuticals (DPH) Share Price, News & Analysis

Company Overview

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, internal medicine, and nutrition products supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. It also provides water soluble antibiotics, vaccines, lameness, pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. In addition, the company distributes veterinary pharmaceuticals and equipment; markets pet diets; and develops, regulates, manufactures, and markets crop protection, as well as offers financial services. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 2.04 million shs
• Average Volume: 1.29 million shs
• Market Capitalization: £4.40 billion
• P/E Ratio: N/A
• Dividend Yield: 1.20%
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: LON:DPH
• CIK: N/A
• Web: www.dechra.com
• Phone: +44-1606-814730
• Fax: N/A
• Employees: 2,457
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): GBX (0.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: 1.42
• Net Income: -£27.90 million
• Net Margins: -3.66%
• Pretax Margin: N/A
• Return on Equity: -3.92%
• Return on Assets: 0.75%

Debt

• Debt-to-Equity Ratio: 66.80
• Current Ratio: 2.85
• Quick Ratio: 1.66

Sales & Book Value

• Annual Sales: £761.50 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 24.43
• Book Value: GBX 663 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 113,910,000
• Free Float: N/A
• Market Cap: £4.40 billion
• Optionable: Not Optionable
• Beta: 0.78